Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Apr 9;5(4):553-555.
doi: 10.1002/hep4.1662. eCollection 2021 Apr.

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes

Weiguo Fan  1   2 , Natalie J Torok  1   2
Affiliations
Editorial

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes

Weiguo Fan et al. Hepatol Commun. .

Abstract

This is an editorial about non-invasive fibrosis markers in patients with NASH and type 2 diabetes mellitus.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Examples of serum biomarkers used to detect fibrosis in NASH trials. Abbreviations: PIIINP, N‐terminal collagen III propeptide; PRO‐C4, C‐terminal pro‐peptide of type IV collagen; and PRO‐C6, C‐terminal pro‐peptide of type VI collagen.
See this image and copyright information in PMC

Comment on

References

    1. El‐Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460‐468. - PubMed
    1. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta‐analysis. J Hepatol 2019;71:793‐801. - PubMed
    1. Bril F, Millán L, Kalavalapalli S, McPhaul MJ, Caulfield MP, Martinez‐Arranz I, et al. Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2018;20:1702‐1709. - PubMed
    1. Luo YI, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, et al. An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis. Sci Rep 2018;8:12414. - PMC - PubMed
    1. Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, et al. Performance of the PRO‐C3 collagen neo‐epitope biomarker in non‐alcoholic fatty liver disease. JHEP Rep 2019;1:188‐198. - PMC - PubMed